Tom Werner
Regenxbio (RGNX) shares fell after the U.S. Food and Drug Administration issued a complete response letter for RGX-121 (clemidsogene lanparvovec), its gene therapy candidate for the treatment of Mucopolysaccharidosis II (MPS II).
The company said it plans to work with